[Featured Stock] Green Cross LabCell Rises on Expectations for Affiliate's Solid Tumor Cell Therapy Preclinical Presentation... 'Up'

[Asia Economy Reporter Hyunseok Yoo] Green Cross LabCell is on the rise. It appears to be influenced by the announcement that its affiliate Artiva will present preclinical results of the solid tumor-targeting CAR-NK cell therapy 'AB-201'.

As of 9:33 AM on the 22nd, Green Cross LabCell was trading at 98,400 KRW, up 1.65% (1,600 KRW) compared to the previous trading day.

On this day, Green Cross LabCell announced that its affiliate Artiva will present preclinical results of the solid tumor-targeting CAR-NK cell therapy 'AB-201' at the Society for Immunotherapy of Cancer (SITC) conference starting on the 10th of next month. Artiva is a corporation established in San Diego, USA, in 2019 by Green Cross LabCell and Green Cross Holdings to develop cell therapies.

According to Artiva, in past animal tests on gastric cancer, AB-201 demonstrated a complete remission effect with tumors disappearing in the body about 33 days after administration. It was also confirmed to have excellent cancer cell elimination and tumor suppression capabilities.